Project 2: Immunotherapy with CMP-001 intratumoral and nivolumab in melanoma

项目 2:使用 CMP-001 瘤内注射和纳武单抗治疗黑色素瘤的免疫疗法

基本信息

项目摘要

PROJECT SUMMARY ABSTRACT: Project 2 Immunotherapy with anti-PD1 monoclonal antibodies (mAbs) is associated with improved response and survival rates in multiple solid tumors, including melanoma1. Anti-PD1 mAbs (anti-PD1) produces durable clinical responses in 33-40% of melanoma patients with minimal toxicity. While dual anti-PD1/anti-CTLA4 blockade produces higher response rates (58%) and 5-year PFS (36%), this is associated with 55% grade 3/4 adverse events. Therefore, there is a critical need for novel combinatorial immunotherapy to improve the efficacy of anti-PD1 while mitigating the rate of serious adverse events in advanced melanoma. One major barrier limiting the efficacy of anti-PD1 is the lack of spontaneous tumor-infiltrating T cells (TILs) and defective IFNa production in tumor microenvironment (TME) in so-called “cold” or non-inflamed tumors. One promising therapeutic approach to overcome this hurdle is via toll-like receptor 9 (TLR9) agonists. TLR9 is predominantly expressed by plasmacytoid dendritic cells (pDCs) and B cells and binds to agonists including unmethylated cytosine guanosine oligodinucleotides (CpG). We have recently performed the first-in-human trial of neoadjuvant intratumoral CMP, a novel type A CpG, and Nivolumab in PD1-naïve high-risk resectable melanoma (NCT03618641). In 30 evaluable melanoma patients, we have observed 60% major pathologic responses with increased CD8+ TILs and peritumoral CD303+ pDCs in injected tumors, and higher frequency circulating PD1+Ki67+CD8+ T cells in responders. Therapy with intratumoral CMP and Nivolumab (CMP/Nivolumab) has also shown clinical efficacy in PD1 refractory melanoma with responses in non-injected tumors, supporting the occurrence of systemic antitumor immunity beyond the injected tumors. To further our understanding of the mechanisms of responses or resistance to CMP/Nivolumab in injected and non-injected tumors, we will take advantage of a substudy of 60 melanoma patients included in the randomized phase II/III clinical trial evaluating CMP/nivolumab vs. nivolumab in PD1 naïve metastatic melanoma with accessible tumors for intratumoral CMP. Based on our preliminary findings, we will investigate whether CMP/Nivolumab :1) increases pDC activation and recruitment into injected tumors to promote CD8+TIL expansion and functions in injected and non-injected tumors; 2) induces melanoma cell death, primes potent neoepitope-specific CD8+T cells in injected tumors, and epitope spreading to melanoma-associated antigens; and 3) fails to induce potent T cell responses because of melanoma cell-extrinsic or melanoma cell-intrinsic mechanisms. Collectively, the findings in this application will improve our understanding of the mechanisms of response and resistance to CMP/Nivolumab in melanoma. They will further support novel combinatorial immunotherapies to further enhance the immunogenicity and clinical activity of CMP/Nivolumab in injected and non-injected tumors of advanced melanoma.
项目摘要:项目2 使用抗PD 1单克隆抗体(mAb)的免疫治疗与改善的应答相关, 包括黑色素瘤在内的多种实体瘤的生存率1。抗PD 1 mAb(抗PD 1)可产生持久的 在33-40%的黑素瘤患者中具有最小毒性的临床反应。而双重抗PD 1/抗CTLA 4 阻断产生更高的缓解率(58%)和5年PFS(36%),这与55%的3/4级相关 不良事件。因此,迫切需要新的组合免疫疗法来改善免疫应答。 抗PD 1的有效性,同时降低晚期黑色素瘤中严重不良事件的发生率。一个主要 限制抗PD 1效力的屏障是缺乏自发性肿瘤浸润性T细胞(TIL)和缺陷性T细胞(TIL)。 在所谓的“冷”或非发炎肿瘤中肿瘤微环境(TME)中的IFNa产生。一个有希望 克服这一障碍的治疗方法是通过Toll样受体9(TLR 9)激动剂。TLR 9主要 由浆细胞样树突细胞(pDC)和B细胞表达,并结合激动剂,包括未甲基化的 胞嘧啶鸟苷寡核苷酸(CpG)。我们最近进行了首次人体试验, 新辅助肿瘤内CMP(一种新型A型CpG)和Nivolumab治疗PD 1初治高危可切除患者 黑色素瘤(NCT 03618641)。在30例可评估的黑色素瘤患者中,我们观察到60%的主要病理性 在注射的肿瘤中具有增加的CD 8 + TIL和肿瘤周围的CD 303 + pDC的应答,以及更高的频率 应答者中的循环PD 1 + Ki 67 + CD 8 + T细胞。肿瘤内CMP和Nivolumab治疗 (CMP/纳武单抗)也显示出在PD 1难治性黑色素瘤中的临床疗效, 肿瘤,支持在注射的肿瘤之外发生全身抗肿瘤免疫。推进我们 了解注射和非注射中对CMP/Nivolumab的反应或耐药性机制 肿瘤,我们将利用随机II/III期纳入的60名黑色素瘤患者的子研究 评估CMP/nivolumab与nivolumab治疗PD 1初治转移性黑色素瘤的临床试验, 肿瘤内CMP。根据我们的初步发现,我们将研究CMP/Nivolumab是否 1)增加pDC活化和募集到注射的肿瘤中以促进CD 8 +TIL扩增和功能 2)诱导黑色素瘤细胞死亡,引发有效的新表位特异性CD 8 +T细胞 注射肿瘤中的细胞,以及表位扩散到黑素瘤相关抗原;以及3)未能诱导有效的 由于黑色素瘤细胞外在或黑色素瘤细胞内在机制引起的T细胞应答。统称 这项应用的发现将提高我们对免疫应答和抵抗机制的理解。 CMP/Nivolumab治疗黑素瘤。他们将进一步支持新的组合免疫疗法, 增强CMP/Nivolumab在注射和非注射肿瘤中的免疫原性和临床活性, 晚期黑素瘤

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HASSANE M ZAROUR其他文献

HASSANE M ZAROUR的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HASSANE M ZAROUR', 18)}}的其他基金

Administrative Core
行政核心
  • 批准号:
    10469632
  • 财政年份:
    2021
  • 资助金额:
    $ 36.97万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10683751
  • 财政年份:
    2021
  • 资助金额:
    $ 36.97万
  • 项目类别:
Project 2: Immunotherapy with CMP-001 intratumoral and nivolumab in melanoma
项目 2:使用 CMP-001 瘤内注射和纳武单抗治疗黑色素瘤的免疫疗法
  • 批准号:
    10469636
  • 财政年份:
    2021
  • 资助金额:
    $ 36.97万
  • 项目类别:
Project 2: Immunotherapy with CMP-001 intratumoral and nivolumab in melanoma
项目 2:使用 CMP-001 瘤内注射和纳武单抗治疗黑色素瘤的免疫疗法
  • 批准号:
    10270232
  • 财政年份:
    2021
  • 资助金额:
    $ 36.97万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10270228
  • 财政年份:
    2021
  • 资助金额:
    $ 36.97万
  • 项目类别:
Targeting TIGIT and PD-1 in Melanoma
靶向黑色素瘤中的 TIGIT 和 PD-1
  • 批准号:
    10164611
  • 财政年份:
    2018
  • 资助金额:
    $ 36.97万
  • 项目类别:
Targeting TIGIT and PD-1 in Melanoma
靶向黑色素瘤中的 TIGIT 和 PD-1
  • 批准号:
    10412050
  • 财政年份:
    2018
  • 资助金额:
    $ 36.97万
  • 项目类别:
Fecal Microbiota Transplant and PD-1 blockade in Melanoma
黑色素瘤中的粪便微生物群移植和 PD-1 阻断
  • 批准号:
    10441408
  • 财政年份:
    2018
  • 资助金额:
    $ 36.97万
  • 项目类别:
Fecal Microbiota Transplant and PD-1 blockade in Melanoma
黑色素瘤中的粪便微生物群移植和 PD-1 阻断
  • 批准号:
    10018469
  • 财政年份:
    2018
  • 资助金额:
    $ 36.97万
  • 项目类别:
Fecal Microbiota Transplant and PD-1 blockade in Melanoma
黑色素瘤中的粪便微生物群移植和 PD-1 阻断
  • 批准号:
    10196995
  • 财政年份:
    2018
  • 资助金额:
    $ 36.97万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 36.97万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 36.97万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 36.97万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 36.97万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 36.97万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 36.97万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 36.97万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 36.97万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 36.97万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 36.97万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了